Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

1.

Tpl2 kinase impacts tumor growth and metastasis of clear cell renal cell carcinoma.

Lee HW, Joo KM, Lim JE, Cho HJ, Cho HJ, Park MC, Seol HJ, Seo SI, Lee JI, Kim S, Jeong BC, Nam DH.

Mol Cancer Res. 2013 Nov;11(11):1375-86. doi: 10.1158/1541-7786.MCR-13-0101-T. Epub 2013 Aug 27.

2.

Tpl2 induces castration resistant prostate cancer progression and metastasis.

Lee HW, Cho HJ, Lee SJ, Song HJ, Cho HJ, Park MC, Seol HJ, Lee JI, Kim S, Lee HM, Choi HY, Nam DH, Joo KM.

Int J Cancer. 2015 May 1;136(9):2065-77. doi: 10.1002/ijc.29248. Epub 2014 Oct 10.

3.

Interleukin-17 induces AP-1 activity and cellular transformation via upregulation of tumor progression locus 2 activity.

Kim G, Khanal P, Lim SC, Yun HJ, Ahn SG, Ki SH, Choi HS.

Carcinogenesis. 2013 Feb;34(2):341-50. doi: 10.1093/carcin/bgs342. Epub 2012 Nov 3.

PMID:
23125217
4.

CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis.

Gassenmaier M, Chen D, Buchner A, Henkel L, Schiemann M, Mack B, Schendel DJ, Zimmermann W, Pohla H.

Stem Cells. 2013 Aug;31(8):1467-76. doi: 10.1002/stem.1407.

5.

Silencing of CXCR4 by RNA interference inhibits cell growth and metastasis in human renal cancer cells.

Wang L, Huang T, Chen W, Gao X, Zhou T, Wu Z, Sun Y.

Oncol Rep. 2012 Dec;28(6):2043-8. doi: 10.3892/or.2012.2028. Epub 2012 Sep 12.

PMID:
22972438
6.

Combined gene expression profiling and RNAi screening in clear cell renal cell carcinoma identify PLK1 and other therapeutic kinase targets.

Ding Y, Huang D, Zhang Z, Smith J, Petillo D, Looyenga BD, Feenstra K, Mackeigan JP, Furge KA, Teh BT.

Cancer Res. 2011 Aug 1;71(15):5225-34. doi: 10.1158/0008-5472.CAN-11-0076. Epub 2011 Jun 3.

7.

High-level S100A6 promotes metastasis and predicts the outcome of T1-T2 stage in clear cell renal cell carcinoma.

Lyu X, Li H, Ma X, Li X, Gao Y, Ni D, Shen D, Gu L, Wang B, Zhang Y, Zhang X.

Cell Biochem Biophys. 2015 Jan;71(1):279-90. doi: 10.1007/s12013-014-0196-x.

PMID:
25120023
8.

miR-141 is a key regulator of renal cell carcinoma proliferation and metastasis by controlling EphA2 expression.

Chen X, Wang X, Ruan A, Han W, Zhao Y, Lu X, Xiao P, Shi H, Wang R, Chen L, Chen S, Du Q, Yang H, Zhang X.

Clin Cancer Res. 2014 May 15;20(10):2617-30. doi: 10.1158/1078-0432.CCR-13-3224. Epub 2014 Mar 19.

9.

Downregulated miR-646 in clear cell renal carcinoma correlated with tumour metastasis by targeting the nin one binding protein (NOB1).

Li W, Liu M, Feng Y, Xu YF, Huang YF, Che JP, Wang GC, Yao XD, Zheng JH.

Br J Cancer. 2014 Sep 9;111(6):1188-200. doi: 10.1038/bjc.2014.382. Epub 2014 Jul 10.

10.

Expression of CX3CR1 associates with cellular migration, metastasis, and prognosis in human clear cell renal cell carcinoma.

Yao X, Qi L, Chen X, Du J, Zhang Z, Liu S.

Urol Oncol. 2014 Feb;32(2):162-70. doi: 10.1016/j.urolonc.2012.12.006. Epub 2013 Apr 6.

PMID:
23570708
11.

Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma.

Ma X, Gu L, Li H, Gao Y, Li X, Shen D, Gong H, Li S, Niu S, Zhang Y, Fan Y, Huang Q, Lyu X, Zhang X.

J Transl Med. 2015 Feb 12;13:56. doi: 10.1186/s12967-015-0421-4.

12.

Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.

Morris MR, Gentle D, Abdulrahman M, Maina EN, Gupta K, Banks RE, Wiesener MS, Kishida T, Yao M, Teh B, Latif F, Maher ER.

Cancer Res. 2005 Jun 1;65(11):4598-606.

13.

Estrogen inhibits renal cell carcinoma cell progression through estrogen receptor-β activation.

Yu CP, Ho JY, Huang YT, Cha TL, Sun GH, Yu DS, Chang FW, Chen SP, Hsu RJ.

PLoS One. 2013;8(2):e56667. doi: 10.1371/journal.pone.0056667. Epub 2013 Feb 27.

14.

Ghrelin promotes renal cell carcinoma metastasis via Snail activation and is associated with poor prognosis.

Lin TC, Liu YP, Chan YC, Su CY, Lin YF, Hsu SL, Yang CS, Hsiao M.

J Pathol. 2015 Sep;237(1):50-61. doi: 10.1002/path.4552. Epub 2015 May 28.

PMID:
25925728
15.

RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways.

Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y.

Eur J Cancer. 2011 Oct;47(15):2353-63. doi: 10.1016/j.ejca.2011.05.006. Epub 2011 Jun 15.

PMID:
21680174
16.

Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.

Ji SQ, Su XL, Cheng WL, Zhang HJ, Zhao YQ, Han ZX.

Urol Oncol. 2014 Feb;32(2):153-61. doi: 10.1016/j.urolonc.2012.09.013. Epub 2012 Dec 27.

PMID:
23273913
17.

Dicer is down-regulated in clear cell renal cell carcinoma and in vitro Dicer knockdown enhances malignant phenotype transformation.

Ma X, Fan Y, Gao Y, Zhang Y, Huang Q, Ai Q, Ni D, Chen W, Zhang P, Song E, Wang B, Shi T, Zheng T, Zhang X.

Urol Oncol. 2014 Jan;32(1):46.e9-17. doi: 10.1016/j.urolonc.2013.06.011. Epub 2013 Oct 4.

PMID:
24094887
18.

MicroRNA-509-3p inhibits cancer cell proliferation and migration by targeting the mitogen-activated protein kinase kinase kinase 8 oncogene in renal cell carcinoma.

Su Z, Chen D, Zhang E, Li Y, Yu Z, Shi M, Jiang Z, Ni L, Yang S, Gui Y, Ye J, Lai Y.

Mol Med Rep. 2015 Jul;12(1):1535-43. doi: 10.3892/mmr.2015.3498. Epub 2015 Mar 17.

PMID:
25815776
19.

Stromal derived factor-1 (SDF-1/CXCL12) and CXCR4 in renal cell carcinoma metastasis.

Pan J, Mestas J, Burdick MD, Phillips RJ, Thomas GV, Reckamp K, Belperio JA, Strieter RM.

Mol Cancer. 2006 Nov 3;5:56.

20.

Repurposing the anti-malarial drug artesunate as a novel therapeutic agent for metastatic renal cell carcinoma due to its attenuation of tumor growth, metastasis, and angiogenesis.

Jeong DE, Song HJ, Lim S, Lee SJ, Lim JE, Nam DH, Joo KM, Jeong BC, Jeon SS, Choi HY, Lee HW.

Oncotarget. 2015 Oct 20;6(32):33046-64. doi: 10.18632/oncotarget.5422.

Supplemental Content

Support Center